tiprankstipranks
Medivir AB (GB:0GP7)
LSE:0GP7
0GP7
Medivir AB
RESEARCH TOOLSreports

Medivir AB (0GP7) Price & Analysis

0 Followers

0GP7 Stock Chart & Stats

kr0.53
-kr0.08(-2.64%)
At close: 4:00 PM EST
kr0.53
-kr0.08(-2.64%)
Day’s Range― - ―
52-Week Rangekr0.40 - kr2.88
Previous CloseN/A
Volume94.00
Average Volume (3M)4.18K
Market Cap
kr1.12B
Enterprise Valuekr1.04K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 20, 2026
EPS Estimate
0
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding617,939,500
10 Day Avg. Volume0
30 Day Avg. Volume4,182
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr54.00
Price Target Upside10088.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)kr5.84M

Medivir AB News

Medivir Expands Share Capital to Fund MIV-711 Orphan Indication
Medivir Expands Share Capital to Fund MIV-711 Orphan Indication
Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB has completed an oversubscribed directed share issue...
6d ago
Medivir Shareholders Approve Directed Issue to Bolster Drug Development
Medivir Shareholders Approve Directed Issue to Bolster Drug Development
Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir AB, a Huddinge-based pharmaceutical developer listed on Nasdaq...
17d ago
Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination
Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination
The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir AB has secured a Notice of...
17d ago
Medivir Expands Share Capital Following First Tranche of Directed Issue
Medivir AB ( ($SE:MVIR) ) just unveiled an update. Medivir AB has updated its share and vote count...
1M ago
Medivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm
Medivir AB ( ($SE:MVIR) ) has issued an announcement. Medivir has prepared and published a disclosure document in...
1M ago
Medivir Calls Extraordinary General Meeting with Expanded Voting Options
Medivir AB ( ($SE:MVIR) ) has shared an announcement. Medivir AB has called an extraordinary general meeting for...
2M ago
Medivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease
The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir has raised approximately SEK 140 million...
2M ago
Medivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug
Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir plans to raise approximately SEK 130 million through...
2M ago
Medivir’s fostrox combo shows promising liver cancer data in key journal
Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB reported that results from a phase 1b/2a...
2M ago
Medivir Begins Key Phase 2 Trial of Fostrox Combo in Advanced Liver Cancer
Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir has announced the enrollment of the first patient...
3M ago

0GP7 FAQ

What was Medivir AB’s price range in the past 12 months?
Medivir AB lowest share price was kr0.40 and its highest was kr2.88 in the past 12 months.
    What is Medivir AB’s market cap?
    Medivir AB’s market cap is kr1.12B.
      When is Medivir AB’s upcoming earnings report date?
      Medivir AB’s upcoming earnings report date is Aug 20, 2026 which is in 14 days.
        How were Medivir AB’s earnings last quarter?
        Medivir AB released its earnings results on May 05, 2026. The company reported kr0 earnings per share for the quarter, beating the consensus estimate of -kr0.091 by kr0.091.
          Is Medivir AB overvalued?
          According to Wall Street analysts Medivir AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Medivir AB pay dividends?
            Medivir AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of N/A. See more information on Medivir AB dividends here
              What is Medivir AB’s EPS estimate?
              Medivir AB’s EPS estimate is 0.
                How many shares outstanding does Medivir AB have?
                Medivir AB has 617,939,500 shares outstanding.
                  What happened to Medivir AB’s price movement after its last earnings report?
                  Medivir AB reported an EPS of kr0 in its last earnings report, beating expectations of -kr0.091. Following the earnings report the stock price went down -2.393%.
                    Which hedge fund is a major shareholder of Medivir AB?
                    Currently, no hedge funds are holding shares in GB:0GP7
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Medivir AB

                      Medivir AB is pharmaceutical research and development company. It develops pharmaceuticals for the treatment of cancer and specializes in protease inhibitor research and nucleotide science. The firm conducts research in all phases of pharmaceutical development from idea to clinical phase III studies. Its project pipeline includes Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323 proprietary projects and also Olysio, JNJ-4178, Xerclear and MIV-802 partnership projects. The firm's products include Xerclear and Simprevir.

                      Medivir AB (0GP7) Earnings & Revenues

                      Historic Earnings Reports

                      0GP7 Stock 12 Month Forecast

                      Average Price Target

                      kr54.00
                      ▲(10088.68% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"kr0","55":"kr55","13.75":"kr13.75","27.5":"kr27.5","41.25":"kr41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,13.75,27.5,41.25,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2022","6":"Aug<br/>2022","9":"Feb<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,5.953846153846154,9.957692307692307,13.96153846153846,17.965384615384615,21.96923076923077,25.97307692307692,29.976923076923075,33.98076923076923,37.98461538461539,41.98846153846154,45.9923076923077,49.996153846153845,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,5.953846153846154,9.957692307692307,13.96153846153846,17.965384615384615,21.96923076923077,25.97307692307692,29.976923076923075,33.98076923076923,37.98461538461539,41.98846153846154,45.9923076923077,49.996153846153845,{"y":54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,5.953846153846154,9.957692307692307,13.96153846153846,17.965384615384615,21.96923076923077,25.97307692307692,29.976923076923075,33.98076923076923,37.98461538461539,41.98846153846154,45.9923076923077,49.996153846153845,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.595,"date":1614556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.595,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.488,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.926,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Detailed Analyst Forecast >

                      Technical Analysis

                      Overall Consensus
                      Strong Buy
                      12Bullish
                      0Neutral
                      1Bearish
                      Bullish
                      Neutral
                      Bearish
                      Overall Consensus
                      12
                      0
                      1
                      Technical Analysis
                      1
                      0
                      0
                      Moving Averages
                      11
                      0
                      1
                      Technical Analysis >
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      5IU
                      Isofol Medical AB
                      ―
                      ―
                      8E8
                      Elicera Therapeutics AB
                      ―
                      ―
                      7ZA
                      Ascelia Pharma AB
                      ―
                      ―
                      6IRA
                      IRLAB Therapeutics AB Class A
                      ―
                      ―
                      ―
                      ―
                      ―
                      Compare GB:0GP7 Stocks >
                      Popular Stocks